Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 12Active not recruiting 4Not yet recruiting 3Suspended 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Allogeneic Stem Cell Transplantation 1

Interventions

pembrolizumab 2fludarabine 2daratumumab 2Temozolomide 2Radiation 2vocimagene amiretrorepvec 1reducing agent and tunicamycin-responsive protein, human 1pelcitoclax 1olutasidenib 1irinotecan sucrosofate 1epacadostat 1ebselen 1dexamethasone acetate 1dexamethasone 21-phosphate 1decitabine and cedazuridine drug combination 1carfilzomib 1balstilimab 1auricularum 1Vorinostat 1Transurethral Resection of Prostate 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy 1Radiofrequency Ablation 1Pluvicto 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Kidney Transplantation 1Irinotecan 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡